secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2026-03-03T23:59:59+00:00
Accession:  0001140361-26-007548
Event type: litigation
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant's Genevant/Arbutus settles Moderna LNP patent suit for $950M upfront, plus $1.3B contingent
--------------------------------------------------------------------------------

- Moderna to pay $950M non-contingent by July 8, 2026; additional $1.3B if Federal Circuit affirms rejection of Section 1498 defense.
- Settlement includes judgment of no invalidity on four Genevant/Arbutus patents and a global non-exclusive license to LNP tech for infectious disease mRNA vaccines.
- Roivant board authorizes $1B share repurchase program (includes prior $500M authorization), no expiration date.
- Genevant/Arbutus continues litigation against Pfizer/BioNTech; Comirnaty sales represent ~2/3 of global COVID mRNA vaccine sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036126007548/0001140361-26-007548-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036126007548/ef20067067_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-007548

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer